K awasaki disease (KD) is an acute vasculitis syndrome first described by Dr Tomisaku Kawasaki in 1967 (1) . It most commonly affects children under the age of 5 years and is typically self-limited. Its classic symptoms include high fever and signs of generalized inflammation of the skin, eyes, mouth, cervical lymph nodes, and palms and soles (2) . The vasculitis affects medium-sized blood vessels, most notably coronary artery abnormalities (CAAs), and can cause chronic alterations in the coronary circulation. CAAs occur in up to 25% of untreated patients (3) , with the most serious consequence being death from acute coronary artery thrombosis (4) .
Intravenous immunoglobulin (IVIg) was first shown in 1984 to reduce the incidence of CAAs in KD patients (5) . A number of dosing regimens were studied, and in 1991, the most effective of those was shown to be a single infusion of 2 g/kg IVIg aspirin administered over 12 h (6) . This dose was instituted in the 1993 American Heart Association (AHA) scientific statement on KD (7) and has been standardly used since then.
Acetylsalicylic acid or aspirin was first proposed as a therapeutic option for KD, given both its anti-inflammatory and anti-platelet effects, when thrombocytosis was recognized as a key feature of the disease 6 years after its initial description (8) . At moderate (30-50 mg/kg per day) and high (80-100 mg/kg per day) doses, aspirin exerts antiinflammatory effects, whereas at lower doses (3-5 mg/kg per day), the predominant effect is that of anti-platelet. The initial recommended dose of aspirin in the acute phase of KD in Japan was 30 mg/kg per day (9, 10) . Simultaneously, data published in the United States demonstrated that malabsorption of aspirin may occur in the acute phase, necessitating higher doses to achieve clinical effects (11, 12) . This notion was supported by the data indicating that aspirin doses of 80-100 mg/kg per day could shorten the duration of fever (4) and, when compared to no aspirin therapy, were associated with a decreased incidence of CAAs (13) .
These early data on the effect of aspirin on CAAs were questioned in 1992 when a multicenter study demonstrated no difference in the incidence of CAAs between patients treated with IVIg and high-dose aspirin (HDA), defined in that trial as 100 mg/kg per day vs. those treated with IVIg and low-dose aspirin (5-10 mg/kg per day) (14) . The same conclusion was reached by a meta-analysis that showed no difference in the incidence of CAAs at 30 or 60 days after disease onset between the low-dose aspirin or HDA groups, with HDA being defined as 480 mg/kg per day (15) . A subsequent meta-analysis showed that the prevalence of CAAs was inversely related to the total dose of IVIg but was independent of the aspirin dose used (16) .
With respect to the effects of aspirin on the duration of fever, which can influence the length of hospitalization, a 1992 study found that HDA was associated with a shorter duration of fever (14) ; however, a more recent comparison of HDA and low-dose aspirin in the treatment of KD showed no difference in fever duration between the two groups (17) .
The conflicting evidence regarding the effects of HDA on CAA incidence and fever duration is reflected in the guidelines for the treatment of KD. In 1988, a consensus statement prepared by North American participants of the Third International Kawasaki Disease Symposium recommended HDA of 80-100 mg/kg per day for 14 days in the management of KD (18) . Five years later, the AHA statement on KD recommended HDA until the patient was afebrile and acknowledging; however, some clinicians recommend HDA until the 14th day of the illness (7) . The 2004 and recently published 2017 AHA statements on KD once again recognized the differences in practices regarding HDA dosing among institutions (19, 20) . Both statements specifically note that HDA "does not appear to lower the frequency of the development of coronary abnormalities," based on evidence evaluating the effect of HDA on CAAs at early follow-up 30 and 60 days after diagnosis (15, 21) . The 2017 AHA statement recommends that "administration of moderate-(30-50 mg/kg per day) to high-dose (80-100 mg/kg per day) aspirin is reasonable until the patient is afebrile, although there is no evidence that it reduces coronary artery aneurysms" (20) . Furthermore, there are no data to indicate the superiority of either the 30-50 mg/kg per day dose used in Japan and Europe or the 80-100 mg/kg per day dose used in the United States (20) .
The purpose of the present study was to evaluate a single center's experience of demographic and illness factors that may affect the clinician practices regarding HDA duration prescribed in acute KD, as well as the impact of HDA duration on key clinical outcomes, including long-term status of CAAs up to 15 months after diagnosis, IVIg resistance, duration of fever, and normalization of inflammatory markers.
METHODS
A retrospective study was performed at the University of Minnesota Masonic Children's Hospital, a tertiary referral center. Medical records of all children with an International Classification of Diseases-9 diagnosis of KD between September 2006 and December 2015 were reviewed. Of 126 patients who met the criteria of acute KD, 103 patients had HDA duration documented and were included in the study. This chart review was approved by the University of Minnesota Institutional Review Board.
During the decade of this study, there was no standardized approach to determine the duration of HDA therapy at our institution. Because numerous providers cared for these patients, there was variability in practice regarding HDA duration. The decision to change from HDA to low-dose aspirin appeared to be influenced by laboratory markers of inflammation or the presence of CAA, but the rationale for the timing of the change was not clearly documented in several cases.
Patients were categorized as having received one of three durations of HDA: 0, 1-7, or 47 days. Demographic and illness variables compared among these three groups included age, sex, race, days of illness before diagnosis, and classic vs. incomplete KD status. Fever was defined as a temperature of 38°C or higher. Criteria for the classic and incomplete KD were defined according to the 2017 AHA statement on KD (20) . Coronary artery dimensions were determined by transthoracic echocardiography and were recorded as body surface area-adjusted Z-scores (22) . The primary outcome measure was the maximum coronary artery Z-score. This measure, along with the secondary outcome measures of C-reactive protein (CRP) and platelet count were compared at the time of diagnosis, at 4-8 weeks after diagnosis, and at 9-15 months after diagnosis. CAAs were defined as the maximum coronary artery Z-score greater than or equal to 2.5 (2) . Other secondary outcomes recorded included days of fever after diagnosis and IVIg resistance. IVIg-resistant patients were defined as those who received more than one dose of 2 g/kg of IVIg and/or additional therapies, including corticosteroids, biologic therapeutics, or other immunosuppressive agents, given at least 36 h since the end of the first IVIg infusion.
Statistical analysis was performed using the SAS software package (version 9.3; SAS Institute Inc., Cary, NC). P values were calculated using one-way analysis of variance for continuous variables and Fisher's exact test for categorical variables. A P value of o0.05 was considered statistically significant. The statistical significance of multiple comparisons was determined using the Bonferroni adjustment (23) . To assess the impact of HDA duration on longitudinal variables, a linear mixed model was used to account for the withinsubject correlation with adjustment for age at diagnosis, sex, and IVIg resistance. A linear regression model with the same adjustments was used to determine the predictors of coronary artery Z-score at 9-15 months in patients who had developed CAAs at diagnosis.
RESULTS

Patient Characteristics
Of 126 patients diagnosed with acute KD in the study time frame, 103 patients had HDA duration documented and were included in the study. Among the included patients, 63 (61%) were male, 68 (66%) were white, and 72 (70%) were under the age of 5 years. Seventeen patients (17%) received 0 days of HDA, 63 patients (61%) received 1-7 days of HDA, and 23 patients (22%) received 47 days of HDA. Of the 103 study patients, 35 (34%) patients had CAAs at diagnosis ( Figure 1 ). Only two of those patients had isolated left main coronary artery dilation; this is a location where Z-scores should be interpreted with caution because of frequent anatomic variations (20) ; however, reviews of the echocardiograms in our two patients indicated obviously dilated vessels (maximum Z-score of 44.24 in one case and 3.54 in the other, with borderline ectasia of the left anterior descending artery in the latter).
Clinical Correlates of HDA Duration
All patients. Within the overall study population, three factors correlated with the duration of HDA prescribed: illness duration before diagnosis, duration of defervescence before diagnosis, and administration of IVIg (Table 1) . Specifically, illness duration and the duration of defervescence before diagnosis were both longer in the 0-day HDA group than in the other two groups (Po0.001 for both variables). Among the 17 patients in the 0-day HDA group, 5 had fever at the time of diagnosis, and all 5 of them received IVIg. Overall, a significantly lower proportion of patients in the 0-day HDA group received IVIg compared with the other groups (68% vs. 98% and 100%, Po0.001). All but one patient who received any HDA received IVIg, whereas 6 of 17 patients in the 0-day HDA group (35% of group) did not receive IVIg. It is unusual for a patient to receive HDA but not IVIg; in this case, the primary care provider started HDA for KD based on the recurrence of a peeling rash several days after an initial 5-day period of fever and rash. However, the consulting cardiologist did not recommend IVIg because the fever had resolved and the echocardiogram was normal; the HDA was then discontinued.
There was no association between patient age, sex, or race, and the duration of HDA in the overall study population. The proportions of patients with classic vs. incomplete KD and with CAAs at the time of diagnosis were also not different between the three HDA groups ( Table 1) . The CRP at diagnosis was not associated with the duration of HDA. There was a statistically significant difference in platelet count at diagnosis between the three HDA groups, with the 0 days of HDA group having the highest value, followed by the 47-day group, and then the 1-7-day group ( Table 1) .
Patients without CAAs at diagnosis. Table 2 contains data regarding the subgroup of 68 patients without CAAs at the time of diagnosis. Within this group, 10 patients (15%) received 0 days of HDA, 45 (66%) received 1-7 days of HDA, and 13 (19%) received 47 days of HDA. Four of the 10 patients who did not receive HDA also did not receive IVIg, whereas only one patient who received HDA did not receive IVIg (described above); pairwise comparison demonstrated a significant difference between the 0-day HDA group and the 1-7-day HDA group for IVIg administration (60% vs. 98%, P = 0.003). As with the overall study population, illness duration and the duration of defervescence before diagnosis were longer in the 0-day HDA group compared within the other two groups (Po0.001 for both variables). The average age at diagnosis was higher in the 0-day HDA group (9.01 years) compared with in the other two groups (3.74 and 2.87 years, Po0.001), whereas the platelet count at diagnosis was higher in the 47-day HDA group (522.5 × 10 9 /L) compared with the other two groups (324.3 × 10 9 /L and 352.7 × 10 9 /L, Po0.001). There was no association between patient sex, race, or KD status, and the duration of HDA prescribed.
Patients with CAAs at diagnosis. Table 3 contains data regarding the subgroup of 35 patients with CAAs at the time of diagnosis. Despite the presence of CAAs at diagnosis, seven patients (20%) received 0 days of HDA; 18 (51%) received 1-7 days of HDA, and 10 (29%) received 47 days of HDA. Two of the seven patients who did not receive HDA also did not receive IVIg, whereas 100% of patients who received HDA also received IVIg. As with the overall study population, illness duration was significantly longer in the 0-day HDA group (29.14 days) compared with the other two HDA groups (9.35 and 11.70 days, Po0.001), whereas the duration of defervescence was longer in the 0-day HDA group compared with the 1-7-day HDA group (12.86 vs. 0.06 days, P = 0.002). The fraction of female patients was higher in the 0-day HDA group (71%) and lowest in the 47-day HDA group (10%).
Similar to the entire study population, there was no association between patient age, race, or KD status and the duration of HDA among patients with CAAs at diagnosis. The maximum coronary artery Z-score value, CRP level, and platelet count at diagnosis were also not correlated with the duration of the HDA prescribed.
Clinical Course and Outcomes Based on the Duration of HDA All patients. Among the overall study population, there was no association between the duration of HDA prescribed and IVIg resistance, fever duration after diagnosis, CRP, or platelet count at 4-8 weeks or 9-15 months ( Table 1) .
Patients without CAAs at diagnosis. Between the three HDA groups, univariate analysis of the 68 patients without CAAs at diagnosis ( Table 2 ) demonstrated a higher CRP at 4-8 weeks in the 0-day HDA group compared with the 1-7-day HDA group (0.83 g/dL vs. 0.32 g/dL, P = 0.03) and a higher platelet count at 4-8 weeks in the 47-day HDA group compared with the 0-day HDA group (417.3 × 10 9 /L vs. 342.0 × 10 9 /L, P = 0.03). However, neither of these variables were different between the HDA groups at 9-15 months. Similar to the overall study population, there was no association between the duration of HDA prescribed and IVIg resistance, or fever duration after diagnosis. No patients without CAAs at the time of diagnosis subsequently developed CAAs.
Patients with CAAs at diagnosis. Among patients with CAAs at the time of diagnosis, CAAs were still present at the 4-8-week timepoint in 19 of 35 patients and continued to persist even at the 9-15 months timepoint in 15 of them ( Table 3 ). Comparing the three HDA groups, univariate Articles | Migally et al. analysis demonstrated a lower incidence of persistent CAAs at 9-15 months in the 1-7-day HDA group compared with the 47-day HDA group (33% vs. 89%, P = 0.01). However, multivariate analysis adjusted for age, sex, and IVIg resistance revealed no correlation between HDA duration and coronary artery dimensions at 9-15 months. Although the platelet count at 9-15 months was higher in the 0-day HDA group compared with the 1-7-day HAD group in univariate analysis (454.3 × 10 9 /L vs. 250 × 10 9 /L, P = 0.02), this difference did not persist in the multivariate analysis. Similar to the overall study population, there was no association between the duration of HDA prescribed and IVIg resistance, fever duration after diagnosis, or CRP at 4-8 weeks or 9-15 months. Longitudinal analysis adjusted for age, sex, and IVIg resistance demonstrated no difference in the rate of decline of coronary Z-score (Figure 2) , CRP, or platelet count between the HDA groups. With respect to persistence vs. resolution of CAAs at 9-15 months ( Table 4 ), univariate analysis revealed that patients with persistent CAAs had longer duration of fever after the diagnosis (6.07 vs.0.67 days, P = 0.03) and higher incidence of IVIg resistance (79 vs.11%, P = 0.003). After adjusting for age, sex, and IVIg resistance, the only factor associated with higher coronary Z-scores at 9-15 months was higher coronary Zscores at diagnosis.
DISCUSSION
This retrospective study of 103 patients with KD was designed to understand the variations in clinical practice around the duration of HDA therapy and how these different durations affect the coronary artery outcomes beyond the acute and subacute phases of the disease. A relatively large fraction of patients in this study did not receive HDA. This group was characterized by a longer duration of illness before diagnosis and the lack of administration of IVIg. Patients who did not receive HDA represent a subset of the KD population in whom defervescence typically occurred before diagnosis as part of a prolonged illness course. Review of the medical charts of these patients indicates that the rationale behind not administering HDA was most commonly that the febrile phase of the illness had ended. However, 5 of 17 patients who had no HDA did have fever at the time of diagnosis; the reasons for not giving HDA in these five cases varied. Of note, low-dose aspirin was administered to 15 of the 17 patients who did not receive HDA; it was withheld in one patient because of the elevation of liver enzymes; and in the other, because of the practitioner's concern about precipitating Reye syndrome. Most importantly, although these factors may influence the clinical decisions regarding initiation of HDA therapy, the duration of HDA therapy itself had no impact on the clinically relevant outcome measures, particularly the late development of or persistence of CAAs and the duration of fever after diagnosis. After adjusting for IVIg resistance, a known risk factor for persistence of CAAs (2, 20) , the only factor associated with higher coronary artery Z-scores at 9-15 months was higher coronary artery Z-scores at diagnosis. This association has been described in early (24) and late (25) follow-up, and may serve as a prognostic predictor of CAA outcomes.
Similar data exist from the 1990s and early 2000s regarding the lack of effect of HDA administration on CAA evolution (14, 15, 16, 21) and fever duration (17) ; however, the 2004 and 2017 AHA statements acknowledge that there is variability in practices regarding HDA dosing among institutions (19, 20) , and our study demonstrates a wide within-institution variability in practice. In addition, these studies and newer Superscripts denote pairwise comparisons of statistical significance for variables with P values o0.05: for no significant differences in pairwise comparison. Bonferroni's adjustment for multiple comparisons is used, whereby a P value threshold for statistical significance between pairs is 0.05/(number of pairwise comparisons) = 0.05/3 = 0.0167. b Superscripts denote pairwise comparisons of statistical significance for variables with P values o0.05: for a significant difference between the 0-day HDA group and the 1-7day HDA group.
ones (26) have largely evaluated the effect of HDA on shortterm outcomes in the acute and subacute phases of the disease, and so it was important to determine whether a particular HDA duration conferred measurable clinical benefit in the convalescent phase and beyond. Based on our study, there was no apparent correlation between the duration of HDA and long-term clinical outcomes, suggesting that HDA may not be necessary in the acute management of KD. Consistent with this suggestion, Dallaire et al. (27) recently reported their findings from a retrospective study comparing HDA (80 mg/kg per day) to low-dose aspirin (3-5 mg/kg per day) in acute KD; they found no difference in the risk of CAA between these two groups, and thus concluded that low-dose aspirin is not inferior to HDA for reducing CAA risk (27) . However, another recent retrospective report found that patients who received low-dose aspirin had three times higher odds of needing IVIg re-treatment compared with those who received HDA, but with no difference in duration of hospitalization or of coronary artery aneurysms (28) .
Determining whether and how HDA should be used in the acute management of KD is important, because HDA has been associated with a number of adverse effects, including transaminitis (29) and rarely, Reye syndrome (30) . Transaminitis was seen in two patients in our study necessitating early discontinuation of HDA, and no cases of Reye syndrome were observed. Notably, our data also identified a small subset of patients with "missed" KD. In particular, three patients who initially had normal echocardiograms and were not treated for KD subsequently presented again and were diagnosed with KD with interval development of CAAs. All three patients had an illness duration of 14 days or longer, and two did not receive HDA. These cases highlight the importance of maintaining a low threshold for the diagnosis and treatment of KD based on the previously established criteria (19, 20) , particularly in the setting of a prolonged illness course.
Our study also highlights the degree of practice variability in the management of KD at our center. In response to the findings presented here, we have now implemented a clinical practice guideline based on the 2017 AHA statement on KD (20) .
Limitations of this study include its single-center and retrospective nature, a relatively small number of patients with CAAs, as well as loss of follow-up data. The latter is particularly true for patients with no CAAs at presentation or at 4-8 weeks, as well as for laboratory values that are occasionally not documented over time. Confounding by indication is common in retrospective studies such as this; indeed, it seems clear that the patients who received no HDA were at a later stage of disease compared with the other two groups. However, there were no clinically meaningful differences in the presenting symptoms, laboratory values, or coronary artery Z-scores between those patients who received 1-7 days of HDA compared with those who received 47 days of HDA in this study, suggesting that prolonged administration of HDA does not influence the outcomes. Of note, 34% of the patients in this study had CAAs at the time of diagnosis. This is a higher percentage than in most centers and underscores the need for a high index of suspicion for KD in children, especially those with incomplete KD who are mostly outside the expected 1-5year age range.
Overall, this study adds to a growing body of literature supporting the notion that the duration of HDA therapy does not influence meaningful long-term clinical outcomes in KD, particularly CAA persistence. These findings highlight an opportunity to design larger, multicenter prospective trials that can provide more generalizable data regarding the interplay between HDA duration and long-term coronary artery outcomes, including the question of whether the routine use of HDA is necessary in the acute management of KD.
